News

On January 19, 2024, the FDA announced the addition of a Boxed Warning to the labeling of denosumab (Prolia), citing evidence of an increased risk of severe hypocalcemia in patients with chronic kidney disease.

This study and its development of the Prurigo Control Test represents the first of its kind to assess chronic prurigo disease control.

Evidence from the Look AHEAD study suggests achieving remission in type 2 diabetes is associated with risk reductions in chronic kidney disease and cardiovascular disease.

A new study found individuals with OCD had an 82% increased risk of all-cause mortality as well as an increased risk of mortality due to natural causes and unnatural causes.

The XGBoost machine learning model outperformed other AI and logistic regression models for predicting DAA failure, with an AUROC of 1.000 in the training dataset and 0.803 in the validation dataset.

This interview segment with Bhatia featured a discussion on addressing both unmet needs and lack of awareness among patients with actinic keratosis.

A new study found critical components of CBT-I are cognitive restructuring, third-wave components, sleep restrictions, and stimulus control.

Patients with IgAN and urine protein levels of 0.75–3.5 g/d treated with corticosteroids exhibited significantly greater overall and complete remission rates compared to those who received supportive care.

Improvements in insulin resistance were reported in patients with RA and type 2 diabetes treated with tofacitinib.

A new study reports previously unknown inherited genetic variants that contribute to glaucoma risk among more than 11,000 people of African ancestry.

Bhatia discussed some of the major takeaways from his Winter Clinical presentation titled ‘What's New and Hot in AK Management.’

Test your knowledge of treatment persistence, adherence, and switching patterns of adalimumab biosimilar ABP 501 between adalimumab-naïve patients and adalimumab-experienced patients.

In this segment of Porter’s interview, she delves further into the phase 2 findings on lutikizumab and discusses any adverse events and future research.

Consuming a 5mg piperine capsule once daily for 12 weeks was linked to several pharmacological improvements in patients with NAFLD.

In a new study, nearly a third of participants with OSA reported using > 3 coping strategies, but participants without OSA reported never using > 3 coping strategies.

Both the FDA and EU regulators indicated visual acuity may serve as primary endpoint to evaluate MCO-010 in the treatment of low-vision retinitis pigmentosa patients.

In the CLEAR Outcomes trial, bempedoic acid was associated with a 20% reduction in relative risk for total cardiovascular events, with further analysis shining light on the effects of specific types of events.

Investigators observed no change in Insomnia Severity Index scores from baseline to weeks 7 and 25 with CBT-1, trazodone, or placebo, suggesting these insomnia treatment options are not effective for patients undergoing hemodialysis.

An analysis of the RAFT trial showed patients with heart failure treated with CRT-D experienced continued survival benefits during a median of nearly 14 years of follow-up.

Renal failure risk group classification based on pathological findings from patients’ kidney biopsy, eGFR, and proteinuria was significantly associated with a composite 50% increase in serum creatinine.

Fracture occurrences were numerically higher among men who received testosterone than placebo across a subtrial of the phase 4 TRAVERSE trial.

The FDA has extended the shelf-life of 4 mg naloxone hydrochloride nasal spray (Narcan) for nonprescription over-the-counter use from 3 years to 4 years.

A number of factors related to reproduction can affect a woman’s risk of rheumatoid arthritis. Test your knowledge with this quiz.

Exposure to higher levels of outdoor artificial light at night exhibited an increased risk of incident wet age-related macular degeneration.

These data indicate that e-cigarettes and nicotine patches were found not to negatively impact pregnant smokers in a significant way, though further study may be valuable.

In an interview, Jacob Ballon, MD, MPH, discusses the significance of his team’s study which found olanzapine and samidorphan was well-tolerable for up to 4 years of treatment for schizophrenia and bipolar disorder treatment.

Analysis finds measures of iron deficiency, including ferritin, serum iron, and transferrin, were linked to an increased likelihood of depression in young adult males but not females.

We sat down with Julie Khlevner, MD, to discuss new efficacy endpoint data from the phase 3 study used to support the FDA approval of linaclotide for pediatric functional constipation.

A multivariable analysis showed that, in a cohort of asthma patients, being at high risk for OSA, women, having uncontrolled rhinitis, and GINA steps 4-5 were linked to uncontrolled asthma.

In this interview, Porter describes some new and encouraging phase 2 data on lutikizumab treatment for patients with HS who had failed anti-TNF therapy.